Log In
BCIQ
Print this Print this
 

Exenatide once weekly suspension

  Manage Alerts
Collapse Summary General Information
Company Bristol-Myers Squibb Co.
DescriptionPremixed suspension of once weekly exenatide, a long-acting release formulation of synthetic exendin-4
Molecular Target Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R)
Mechanism of ActionGlucagon-like peptide-1 (GLP-1) receptor agonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase III
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today